Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
midodrine + octreotide + albumin
- Development stage
- Phase 3
- Lead developer
- Università di Padova
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Administration
- Oral, Subcutaneous, Intravenous
01
Overview
Midodrine + octreotide + albumin is a combination therapy investigated by the University of Padova for the treatment of hepatorenal syndrome (HRS) in patients with cirrhosis. Midodrine is a small molecule alpha-1 adrenergic agonist that induces systemic vasoconstriction to counteract the arterial vasodilation associated with advanced cirrhosis. Octreotide, a somatostatin analogue, is administered to inhibit the release of endogenous vasodilators such as glucagon, thereby reducing splanchnic blood flow. Albumin is used as a plasma volume expander to improve effective circulating volume and renal perfusion. This specific regimen was evaluated in a randomized controlled trial led by the University of Padova and published in 2015, which demonstrated that the combination was significantly less effective than terlipressin plus albumin in achieving HRS reversal.
- Other names
- midodrine plus octreotide plus human albuminmidodrine-octreotide-albumin
02
Targets
ADRA1A (α1A)SSTR2 (Somatostatin receptor type 2)SSTR5 (Somatostatin receptor 5)SSTR (Somatostatin receptors)
Beyond the preview
Go deeper on midodrine + octreotide + albumin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on midodrine + octreotide + albumin.